Background {#Sec1}
==========

Phenazopyridine is a commonly used over-the-counter medication for treatment of symptoms associated with urinary tract infections. In medical education, phenazopyridine is considered a classic cause of drug-induced methemoglobinemia. However, phenazopyridine-induced methemoglobinemia is relatively rare with fewer than ten cases reported over the past 35 years \[[@CR1]--[@CR5]\]. We describe a case of phenazopyridine-induced methemoglobinemia that is unique for three reasons. First, the initial clinical presentation was suggestive of other, common causes of hypoxia. Second, the clinical presentation differs from the few cases of phenazopyridine-induced methemoglobinemia reported in the medical literature. Finally, in this case, the patient presented to a free-standing emergency department (ED) with limited diagnostic and treatment capability compared to a hospital-based facility. However, with thorough history-taking and physical exam, the correct diagnosis was suspected and decision to treat was made after ruling out pulmonary embolism upon arrival to the hospital.

Case presentation {#Sec2}
=================

A 57-year-old female with medical history significant for seizures and breast cancer status-post mastectomy presented to a free-standing ED with chief complaint of headaches, lethargy, diarrhea, and light headedness. She had been treated with neoadjuvant therapy for the breast cancer 12 years prior to admission and was in remission at the time of presentation. The patient reported dysuria, urinary frequency, and urgency 2 days prior to admission for which she took over-the-counter phenazopyridine for symptom relief. Over the subsequent 48 h, she took approximately 24 tablets for persistent symptoms, and started to develop a headache, lethargy, and light-headedness, prompting the visit to the free-standing ED. The patient denied fevers, productive sputum, or recent changes in her regular medications apart from starting the phenazopyridine. Her medications included amitriptyline, cetirizine, clonazepam, diclofenac gel, fluticasone, pramipexole, pregabalin, and vitamin D supplements.

While in the ED, the patient was noted to be tachycardic to 100--110, blood pressure 146/77, and respiratory rate 18 with clear breath sounds bilaterally, but pale and cyanotic appearing lips, hands, toes, with pulse oximeter readings of 80--88%. Chest X-ray did not show focal infiltrates. A non-contrasted head CT scan was negative. A basic metabolic panel was unremarkable, the white blood cell count was normal, but the hemoglobin was 10.5 g/dl and hematocrit 33.6%. The patient was placed on supplemental oxygen via nasal cannula with no change in her O~2~ saturations via pulse oximetry. Urinalysis showed positive white blood cells and was noted to be a deep red-orange color (attributed to the phenazopyridine).

Given continued hypoxia despite supplemental oxygen administration and in the context of phenazopyridine use, prior malignancy, and lack of current anticoagulation, drug-induced methemoglobinemia and pulmonary embolus were considered the most likely diagnoses. An arterial blood gas (ABG) was obtained and revealed a PO~2~ 151 mmHg and arterial O~2~ saturation of 99% making methemoglobinemia the most likely diagnosis. The blood was noted to be dark. This free-standing ED does not have capabilities to test co-oximetry and did not have methylene blue available, so the patient was transferred to the hospital-based ED where she was found to have a methemoglobin level of 24.2% on arterial blood gas and CT chest negative for pulmonary embolus. Methylene blue (100 mg intravenous) was administered with near immediate improvement in oxygenation and headache.

Upon hospital admission to the internal medicine service, the patient was started on nitrofurantoin for a urinary tract infection and did not require additional doses of methylene blue. Her methemoglobin level improved to 5.6% the following day. Her oxygenation remained appropriate throughout the hospitalization. The patient was discharged with resolution of symptoms and has remained symptom free.

Discussion {#Sec3}
==========

Phenazopyridine-induced methemoglobinemia is rarely seen in the emergency setting and few cases relating directly to this medication are cited in the literature \[[@CR1]--[@CR5]\]. Cases of drug-induced methemoglobinemia are more frequently related to use of local anesthetic agents and dapsone \[[@CR5]--[@CR10]\]. Medications that have been associated with acquired methemoglobinemia are listed in Table [1](#Tab1){ref-type="table"} \[[@CR5]--[@CR20]\]. Nevertheless, phenazopyridine is a commonly used over-the-counter medication for symptoms of urinary tract infection that can cause significant methemoglobinemia.Table 1Medications associated with acquired methemoglobinemiaDrug classMedications implicated in cases of methemoglobinemiaAnalgesicsAcetaminophen (generally in overdose or combination with other oxidative stresses), Buprenorphine-naloxone, Celecoxib, Ibuprofen, PhenazopyridineAnestheticsBenzocaine, Lidocaine, Prilocaine (including topical creams), TetracaineAntiemeticsMetoclopramideAntimicrobialsAtovaquone, Dapsone, Sulfonamides (sulfanilamide, sulfamethoxazole, sulfapyridine, sulfathiazide), Quinolones (chloroquine, primaquine)VasodilatorsAmyl nitrate, Nitric oxide, Nitroglycerine, NitroprussideXenobioticsAniline dyes, Naphthalene, Nitrates (ex: well water contamination), Nitrites (ex: fermented meats), Silver nitrate, Trinitrotoluene

Methemoglobinemia can be congenital or acquired \[[@CR10]\]. Congenital causes are seen in cytochrome b5 reductase deficiency or hemoglobin M disease. All patients with hereditary methemoglobinemia should avoid exposure to aniline derivatives, nitrates, and other agents that may precipitate methemoglobinemia.

Methemoglobin forms when the ferrous (Fe~2~+) irons of heme are oxidized to the ferric (Fe~3~+) state. In the ferric state, methemoglobin is unable to bind oxygen. In addition, the oxygen affinity of any remaining ferrous heme in the hemoglobin tetramer is increased. As a result, the oxygen dissociation curve is shifted, resulting in hypoxia, cellular asphyxiation, and resultant lactic acid production \[[@CR9], [@CR10]\].

Induced or acquired methemoglobin typically manifest as a drug reaction. Methemoglobinemia may be suspected by the presence of clinical cyanosis in the presence of a normal arterial pO~2~ on arterial blood gas. The blood in methemoglobinemia has been described as "chocolate-brown," red, or brownish to blue in color, which, unlike deoxy-hemoglobin, does not change color despite the addition of oxygen. Clinical manifestations occur when methemoglobin production is accelerated beyond the capacity of intrinsic NADPH methemoglobin-reductase activity.

To reverse methemoglobinemia, ferric hemoglobin must be reduced to ferrous hemoglobin by either of two pathways. The primary pathway is the NADH-dependent reaction catalyzed by cytochrome b5 reductase \[[@CR10]\]. The alternate pathway uses nicotinamide adenine dinucleotide phosphate (NADPH) generated by glucose-6-phosphate dehydrogenase (G6PD) in the hexose monophosphate shunt to reduce ferric hemoglobin to ferrous hemoglobin, allowing for return to normal oxygen delivery, but this is not significantly active in normal physiology \[[@CR10]\]. Extrinsic electron acceptors, i.e., methylene blue or ascorbic acid, are required for the activation of this pathway \[[@CR10], [@CR20]\].

Symptoms of clinically significant methemoglobinemia are vague, including headache, fatigue, dyspnea, and lethargy. In asymptomatic patients, usually with methemoglobin levels less than 20%, no therapy other than discontinuation of the offending agent will be sufficient \[[@CR10], [@CR20]\]. Patients with acute acquired methemoglobinemia may be symptomatic at lower levels of methemoglobin. Methylene blue therapy is indicated in symptomatic patients, or if the methemoglobin level is greater than 20% of hemoglobin profile on arterial blood gas.

At methemoglobin levels greater than 40%, respiratory depression, altered consciousness, shock, seizures, and death may occur. Hyperbaric oxygen, blood transfusion, or exchange transfusion may be helpful for patients in extremis \[[@CR20]\]. A further discussion of symptoms associated with increasing methemoglobin concentrations is shown in Table [2](#Tab2){ref-type="table"} \[[@CR20]\].Table 2Symptoms observed at increasing levels of methemoglobinMethemoglobin %Symptoms\< 3% (Normal)None3--15%Possibly asymptomatic, low saturations on pulse oximeter, gray skin15--20%"Chocolate-brown" blood, cyanosis20--50%Dizziness, syncope, headache, dyspnea, exercise intolerance, weakness50--70%Central nervous system depression, dysrhythmias, acidosis, seizures, coma\> 70%Profound hypoxia, death

Methylene blue provides an artificial electron transporter for the ultimate reduction of methemoglobin via the NADPH-dependent pathway. The dose of 1 to 2 mg/kg is given intravenously over several minutes to avoid painful local irritation and the response is usually rapid, occurring over the next few minutes \[[@CR10], [@CR20]\]. Repeated dosing may be considered if the level of methemoglobin is still high or the patient remains symptomatic after 1 h, but retreatment is rarely necessary \[[@CR10], [@CR20]\]. If repeated treatment fails to significantly reverse methemoglobin levels, the oxidant stress may have not been fully isolated and decontamination of the skin must be assured and possible gut decontamination considered \[[@CR20]\]. However, patients with sulfhemoglobinemia (a methemoglobinemia mimic) and those with NADPH methemoglobin reductase deficiency may not improve despite methylene blue administration. For refractory cases of methemoglobinemia, hyperbaric oxygen and exchange transfusions may be beneficial, but are cost and time intensive and should be considered in the most extreme of cases \[[@CR20]\].

In patients with G6PD deficiency, methylene blue can induce a hemolytic crisis \[[@CR20]\]. In areas with high prevalence of G6PD deficiency, ascorbic acid (vitamin C) can be given in lieu of methylene blue in order to reduce the chances of inducing a hemolytic crisis \[[@CR20]\]. It should be noted that if methylene blue is available, that treatment with ascorbic acid is not indicated for patients without G6PD deficiency \[[@CR20]\].

For patients requiring dapsone treatment in which methemoglobin is noted, cimetidine can help reduce the oxidative stress and should be administered along with methylene blue in cases of dapsone overdose \[[@CR20]\].

Conclusions {#Sec4}
===========

In the described case, the decision to treat was largely based on clinical grounds. While other causes for tachycardia and hypoxia were considered on her arrival to the facility, the likelihood of methemoglobinemia combined with the relatively low risk from presumptive treatment with methylene blue led the team to recommend treatment as both a diagnostic and therapeutic maneuver. Clinical suspicion was confirmed with laboratory testing once available and other life-threatening diagnoses such as pulmonary embolus subsequently ruled out in due course. Of the cases described in the literature, most are due to relatively young patients taking few other medications and with limited past medical histories. Though methemoglobinemia secondary to phenazopyridine is rare, this case shows that in patients with complex medical histories, it is important to remember that this common and easily accessible medication can precipitate life-threatening hypoxia while also assessing for other, more common potential causes. This case serves to emphasize the importance of a thorough history and physical---tools especially helpful when at a satellite facility with relatively limited resources compared to those available in a hospital-based ED.
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